On June 12, 2017, the U.S. Supreme Court issued its decision in Amgen Inc. v. Sandoz Inc., a case surrounding biosimilars and the interpretation of certain provisions under the Biologics Price Competition and Innovation Act (BPCIA). The decision reversed the Federal Circuit's ruling and concluded that biosimilar makers need not wait for approval before supplying 180-day notice of sales under the BPCIA. The Supreme Court also asked the Federal Circuit to decide whether state law is preempted by the BPCIA. Law360 contacted Finnegan partner Sanya Sukduang for his thoughts on the decision.
He said, "What [the question of whether state law is preempted] does is potentially give rise to different decisions on the disclosure issue, depending on the state that you're in." When asked whether he thinks the Food and Drug Administration (FDA) will intervene and provide its own interpretation of the BPCIA, Sukduang said, "The FDA for years has been saying ... that they don't want to be involved in that—that their job is determining safety and efficacy."
Amgen Inc. v. Sandoz Inc., Biologics Price Competition and Innovation Act (BPCIA), Supreme Court of the United States (SCOTUS)
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.